Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

Maraviroc Dose May Be Too Low for Many African-American People with HIV

A standard dose of the CCR5 antagonist maraviroc (Selzentry) may not be effective for many black people with HIV due to a genetic variation which increases production of a cytochrome P450 protein that speeds up processing of the drug, according to a study published in the August 12 advance edition of Drug Metabolism and Disposition.

alt

Read more:

AIDS 2014: Single-tablet HIV Regimens Not Necessarily More Durable

Antiretroviral therapy (ART) regimens consisting of 1 pill taken once-daily -- known as single-tablet regimens -- were not associated with a longer time to treatment discontinuation when compared to some other modern, well-tolerated regimens that involve more pills or twice-daily dosing, according to a study presented at the 20th International AIDS Conference last month in Melbourne.

alt

Read more:

AIDS 2014: Dolutegravir Demonstrates Good Efficacy Despite Resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who were resistant to NRTIs. Among people starting treatment for the first time, no resistance was detected through 96 weeks, according to study findings presented at the 20th International AIDS Conference last week in Melbourne.

alt

Read more:

AIDS 2014: Switching ART with Suppressed Viral Load Linked to Treatment Failure

People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20thInternational AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as adherence difficulties or treatment changes due to pregnancy.

alt

Read more:

AIDS 2014: Maraviroc Fails To Match Truvada for First-Line HIV Treatment

A NRTI-sparing dual antiretroviral regimen containing maraviroc (Selzentry) plus ritonavir-boosted darunavir (Prezista) was found to be less effective than a standard combination with tenofovir/emtricitabine (the drugs in Truvada), according to findings from the MODERN study presented this week at the 20th International AIDS Conference in Melbourne.

alt

Read more: